Since the beginning of 2023, and as of 5 December 2023, two MERS-CoV cases have been reported with the date of onset in 2023 by the United Arab Emirates (1) and Saudi Arabia (1).
Since the beginning of 2023, and as of 5 December 2023, two MERS-CoV cases have been reported with the date of onset in 2023 by the United Arab Emirates (1) and Saudi Arabia (1).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 26 November - 2 December 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.
Overview of all the data available on the COVID-19 pandemic, including the The European Respiratory Virus Surveillance Summary (ERVISS) and variants of concern.
Despite good access to effective antibiotics, Streptococcus pneumoniae (pneumococci) is still a major cause of disease and death in both developing and developed countries. Pneumococci are the main cause of bacterial respiratory tract infections, such as pneumonia, middle ear infection, and sinusitis, in all age groups.
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.